Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
213results about How to "High cytotoxic activity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods and compositions for the treatment of persistent infections
ActiveUS20070122378A1Reduced activityReduce expressionAntibacterial agentsOrganic active ingredientsMicrobiologyPathology
The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
Owner:DANA FARBER CANCER INST INC +3
Chimeric antigen receptor
ActiveUS20140242701A1High expressionHigh cytotoxic activityAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenAntigen receptor
Provided are a chimeric antigen receptor comprising an extracellular domain capable of binding to an antigen, a transmembrane domain and at least one intracellular domain, the chimeric antigen receptor being characterized in that an intracellular domain of a glucocorticoid-induced tumor necrosis factor receptor (GITR) is contained as the intracellular domain; a nucleic acid encoding the chimeric antigen receptor; a cell expressing the chimeric antigen receptor; and a method for producing the cell.
Owner:MIE UNIVERSITY
Anti-glypican 3 antibody
ActiveUS20070190599A1High cytotoxic activityAnimal cellsSugar derivativesAnticarcinogenHumanized antibody
An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.
Owner:CHUGAI PHARMA CO LTD
Recombinant antibody and antibody fragment
InactiveUS6989145B2Reduce in quantityHigh cytotoxic activitySenses disorderAntibody mimetics/scaffoldsDiseaseDiagnostic agent
A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.
Owner:KYOWA HAKKO KIRIN CO LTD
Method for the selection of antibodies against bcma
ActiveUS20150368351A1High cytotoxic activityHigh activityAnimal cellsCompound screeningNf κb activationAntibody
An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-κB activation, BAFF-dependent NF-κB activation, and does not alter NF-κB activation without BAFF and APRIL is useful as a therapeutic agent.
Owner:BRISTOL MYERS SQUIBB CO
Methods and compositions for the treatment of persistent infections
ActiveUS8652465B2Reduced activityReduce expressionAntibacterial agentsOrganic active ingredientsVirologyChronic infection
The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
Owner:DANA FARBER CANCER INST INC +3
Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
InactiveUS20110236374A1High cytotoxic activityAntibacterial agentsAntipyreticA-DNABULK ACTIVE INGREDIENT
The present invention relates to a genetically recombinant antibody composition which specifically binds to ganglioside GM2, which has higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
Owner:KYOWA HAKKO KIRIN CO LTD
Method used for in vitro proliferation of NK cells
ActiveCN103756963AIncrease lethalityEasy to synthesizeBlood/immune system cellsSerum free mediaPeripheral blood mononuclear cell
Owner:SHANGHAI CLAISON BIOTECH
Methods for Enhancing Natural Killer Cell Proliferation and Activity
InactiveUS20130011376A1Function increaseHigh cytotoxic activityOrganic active ingredientsBiocideNatural killer cellCytokine
Methods of ex-vivo culture of natural killer (NK) cells are provided and, more particularly, methods for enhancing propagation and / or functionality of NK cells by treating the cells with a nicotinamide or other nicotinamide moiety in combination with cytokines driving NK cell proliferation. Also envisioned are compositions comprising cultured NK cells and therapeutic uses thereof.
Owner:GAMIDA CELL
Use of ADCC-optimized antibodies for treating low-responder patients
ActiveUS7713524B2Good treatment effectGood effectAntibacterial agentsImmunoglobulins against blood group antigensCD16Monoclonal antibody
The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V / F heterozygote polymorphism.
Owner:LABE FR DU FRACTIONNEMENT & DES BIOTECH SA
Method for in-vitro amplification of NK cells
InactiveCN102994449AEasy to synthesizeIncrease lethalityBlood/immune system cellsSerum free mediaPeripheral blood mononuclear cell
The invention relates to a method for in-vitro amplification of NK cells, and in particular relates to a method for massive in-vitro amplification of NK cells, wherein the method comprises the following steps of: a, inoculating a peripheral blood mononuclear cell in a CD3McAb and CD226McAb pre-coated culture bottle for coculture; b, adding 1L-2 and 1L-18, coculturing for 72hours to stimulate amplification of NK cells; c, transferring the NK cells, K562 cells after lethal treatment and a serum-free medium containing 1L-2 and 1L-18 in a cell culture bag for coculture; and d, collecting the NK cells. According to the method for in-vitro amplification of the NK cells, two antibodies CD3McAb and CD226McAb are simultaneously coated, so the cell factor synthesis and ADCC effect are promoted, and killing toxicity of the NK cells is remarkably improved; the activation and amplification on the NK cells are achieved just by the 1L-2 and 1L-18 cell factors, so the amplification multiple and cell toxicity of the NK cells are guaranteed, and the cost of cell culture is reduced.
Owner:SHANGHAI CLAISON BIOTECH
Method for simultaneous and efficient amplification of CD<3+>CD<56+>CIK cells and CD<3->CD<56+>NK cells
ActiveCN104357390AHigh purityHigh activityBlood/immune system cellsAdoptive cellular immunotherapySerum free media
The invention discloses a method for simultaneous and efficient amplification of CD<3+>CD<56+>CIK cells and CD<3->CD<56+>NK cells. The method comprises the steps as follows: the concentration of separated PBMC (peripheral blood mononuclear cells) is adjusted by a serum-free medium containing autologous plasma, an Anti-CD16 antibody, IL-2 and IL-15 are added, and then the mixture is transferred into a T175 culture flask for culture; an Anti-CD3 antibody and an Anti-CD137 antibody are added; a serum-free medium containing the autologous plasma, IL-2 and IL-15 is supplemented every two days according to the cell growth condition; the cell concentration is controlled to be about 1.5*10<6> / ml; and after culture is performed for 14-21 days, large quantities of high-purity CD<3+>CD<56+>CIK cells and CD<3->CD<56+>NK cells can be obtained simultaneously, and the total cell quantity can reach an effective value of the cell quantity required for adoptive cellular immunotherapy clinically for tumor. The method for simultaneous and efficient amplification of the CD<3+>CD<56+>CIK cells and the CD<3->CD<56+>NK cells is simple, convenient, effective and high in cell killing activity.
Owner:HRYZ (SHENZHEN) BIOTECH CO +1
Bispecific antibodies against cd3epsilon and ror1
PendingUS20170306018A1Low magnitudeHigh cytotoxic activityImmunoglobulins against cell receptors/antigens/surface-determinantsAntineoplastic agentsBispecific antibodyROR1
Owner:BRISTOL MYERS SQUIBB CO +1
Chimeric antigen receptor
ActiveUS9175308B2High expressionHigh cytotoxic activityPolypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigenTumor necrosis factor receptor
Provided are a chimeric antigen receptor comprising an extracellular domain capable of binding to an antigen, a transmembrane domain and at least one intracellular domain, the chimeric antigen receptor being characterized in that an intracellular domain of a glucocorticoid-induced tumor necrosis factor receptor (GITR) is contained as the intracellular domain; a nucleic acid encoding the chimeric antigen receptor; a cell expressing the chimeric antigen receptor; and a method for producing the cell.
Owner:MIE UNIVERSITY
Method for treating Th2-mediated disease
InactiveUS7666418B2Reduce in quantityHigh cytotoxic activitySenses disorderAntibody mimetics/scaffoldsDiagnostic agentTh2 cytokines
Owner:KYOWA HAKKO KIRIN CO LTD
Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
InactiveUS20120184535A1Improve effectivenessInhibitory activityBiocideNervous disorderDiseaseTyrosine
A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine / threonine and tyrosine kinases and a serine / threonine and tyrosine kinases modulating agent. Novel small-molecule compounds with kinase inhibitory activity, having superior properties as pharmaceutical agents, production method thereof and uses thereof. In particular, new derivatives of tetrahalogenated benzimidazole with serine / threonine and tyrosine kinases inhibitory properties, preferably selected from the group of PIM, HIPK, DYRK, CLK, CDK, FLT, PKG, Haspin, MER, TAO, MNK, TRK kinases which exhibit superior pharmacological actions, and can be useful for the treatment of disease conditions, especially cancers depending on serine / threonine and tyrosine kinases, such as but not limited to leukemias and solid tumors.
Owner:SELVITA SA
Process for producing cytotoxic lymphocyte
ActiveUS20050227354A1High cytotoxic activityImprove expression levelAntibacterial agentsConnective tissue peptidesLymphocyteCytotoxicity
The present invention relates to a method for preparing a cytotoxic lymphocyte characterized in that the method comprises the step of carrying out at least one of induction, maintenance and expansion of a cytotoxic lymphocyte in the presence of fibronectin, a fragment thereof or a mixture thereof.
Owner:TAKARA HOLDINGS
Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
InactiveUS20170306044A1Low magnitudeHigh cytotoxic activityHybrid immunoglobulinsTransferasesBispecific antibodyOvarian cancer
Bispecific antibodies against CD3epsilon and ROR1 are useful for use in the treatmentof ovarian cancer.
Owner:ENGMAB SARL
Potentiation of Anti-cancer activity through combination therapy with ber pathway inhibitors
InactiveUS20130030237A1Potentiate effectivenessPotentiate cytotoxic activityBiocideAnimal repellantsDrugIsrapafant
Provided herein are pharmaceutical compositions and methods of treating cancer wherein the cytotoxic activity of an anticancer agent is potentiated by the combination of base excision repair (BER) pathway inhibitors.
Owner:TRACON PHARMA
Drug for cancer therapy
InactiveUS7419667B2High cytotoxic activityHigh activityBiocidePeptide/protein ingredientsHydrolysateBULK ACTIVE INGREDIENT
A lactoferrin hydrolysate mixture or lactoferrin partial peptide that can be obtained by hydrolyzing lactoferrin with a hydrolytic enzyme and has an action of enhancing cytotoxic activity of an antibody drug in an antibody therapy of cancer is used as an active ingredient of a drug for enhancing cytotoxic activity of an antibody drug in an antibody therapy of cancer.
Owner:MORINAGA MILK IND CO LTD
Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
ActiveUS20140178370A1Reduced activityReduce expressionAntibacterial agentsOrganic active ingredientsProgrammed cell death 1Chronic infection
The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
Owner:EMORY UNIVERSITY +3
Preparation method for CIK cell with high proliferation and high cell cytotoxic activity
InactiveCN101063108AHigh cytotoxic activityIncrease the amplification factorBlood/immune system cellsHigh cellSide effect
The invention discloses a preparing method of high genitality and high cell toxic activity CIK cell, which comprises the following steps: adding gene recombination human cytokine IFN-gamma, CD3 single antibody protein and gene recombination human cytokine IL-2, IL-12 and IL-1 into individual nucleate cell; culturing for 7-24 days under 37 deg. c with CO2 density at 5% and humidity at 100%' getting high genitality and high cell toxic activity CIK cell. This invention increases augmentation multiple and decreases toxic side effect of single cytokine, which can make cell toxic activity maintain 2-3 weeks.
Owner:HARBIN MEDICAL UNIVERSITY
Cytotoxic ribonuclease variants
ActiveUS7655757B2Low affinityHigh cytotoxic activityPeptide/protein ingredientsHydrolasesRNase PHCytotoxicity
Owner:WISCONSIN ALUMNI RES FOUND
Antibody-rnase-conjugate
InactiveUS20100015661A1Strong specificityHigh cytotoxic activityPolypeptide with localisation/targeting motifHydrolasesCytotoxicityConjugated protein
The present invention provides a novel antibody-RNase conjugate which is a single chain protein, providing both the specificity of its antibody portion and the RNase activity of its RNase portion, resulting in an antigen specific effectiveness against cells when applied in vivo or in vitro, wherein the RNase portion is effectively cytotoxic in at least a fraction of cells presenting the antigen, e.g. after internalization by endocytosis. In detail, the present invention provides scAb-RNase conjugate having the principal structure of scFvFc-RNase. This structure could also be shown to allow the effective production of antigen-specific and cytotoxic conjugate protein in cell culture, the conjugate having a high activity with respect to antigen specificity and cyto toxicity.
Owner:MAB FACTORY
Tumor binding specific gamma delta TCR gene modified alpha beta T cell and cancer suppression application thereof
ActiveCN105296431ABroad anti-tumor effectNo cytotoxic activityMammal material medical ingredientsGenetic engineeringCytotoxicityT cell
The invention relates to a tumor binding specific gamma delta TCR gene modified alpha beta T cell and cancer suppression application thereof. The alpha beta T cell expresses the tumor binding specific gamma delta TCR; the tumor binding specific gamma delta TCR comprises a gamma 4 chain and a delta 1 chain; the amino acid sequence of the delta 1 chain CDR3 is shown as SEQ ID NO: 1. Experiment results prove that the cell has cytotoxicity for a plurality of tumor cells, and a novel method and a novel strategy are provided for adoptive immunotherapy of tumors.
Owner:北京佳德和细胞治疗技术有限公司
Cyclin imide peptidyl metalloprotease inhibitor and its application
InactiveCN1974554ANo cytotoxic activityHigh cytotoxic activityOrganic active ingredientsDipeptidesEndopeptidaseDrug
The present invention provides one kind of powerful peptide-like metalloprotease inhibitor, which exhibits obvious selectivity between endopeptidase and exopeptidase and may be used in treating diseases with abnormal active expression of metalloprotease effectively. Specifically, the present invention relates to the peptide-like compound in the general expression as shown, and its optical isomers, pharmaceutically acceptable salts, solvates and medicine precursor. The present invention also relates to the medicine composition containing the peptide-like compound and its medicinal use.
Owner:SHANDONG UNIV
Composition for stimulating and inducing single karyocyte to be amplified to gamma deltaT cell and application of composition
ActiveCN108220239AImprove proliferative abilityHigh purityBlood/immune system cellsCell culture active agentsHigh cellPeripheral blood mononuclear cell
The invention relates to a composition for stimulating and inducing a single aryocyte to be amplified to a gamma delta T cell. The composition is prepared from zoledronic acid, anti-human CD3Ab, anti-human CD28Ab, IL-15, IL-21 and IL-2. The invention also provides a method for the in-vitro mass amplification of gamma deltaT cells by utilizing the composition, and particularly relates to a method for in-vitro inducing the mass amplification of gamma deltaT cells by utilizing PBMCs. The zoledronic acid is used for induction and activation, the anti-human CD3Ab, the anti-human CD28Ab, IL-15, IL-21 and IL-2 are used for inducing and activating the proliferation, and various amplification factor combinations to jointly stimulate and induce the amplification of gamma deltaT cells, and the obtained gamma deltaT cell has the characteristics of large quantity, high purity, high cell toxicity and the like and has good clinical application value.
Owner:安徽瑞达健康产业有限公司
Chinese herbal immunopotentiator for chicken
ActiveCN101856387AEnhance chicken disease resistanceImprove immunityPharmaceutical delivery mechanismImmunological disordersDiseaseAstragalus
The invention relates to a Chinese herbal immunopotentiator for chicken as oral liquid comprising the following raw materials in parts by weight: 4-5 parts of Echinacea purpurea, 2-4 parts of hoantchy root, 0.5-1.5 parts of rhodiola root, 1-3 parts of Dangshen and 0.5-1.5 parts of liquorice. The Chinese herbal immunopotentiator for chicken is prepared by the following steps of: crashing the raw materials, mixing, boiling with water for leaching, concentrating and encapsulating. The Chinese herbal immunopotentiator for chicken has better effects of reinforcing the disease resistance and the disease prevention of chicken and increasing immunizing power.
Owner:石家庄燕科生物科技有限公司
Antioxidant enhancement of therapy for hyperproliferative conditions
InactiveUS7071158B2Good curative effectHigh cytotoxic activityBiocidePeptide/protein ingredientsAntioxidantCytotoxicity
A method to enhance the cytotoxic activity of an antineoplastic drug comprising administering an effective amount of the antineoplastic drug to a host exhibiting abnormal cell proliferation in combination with an effective cytotoxicity-increasing amount of an antioxidant. The invention also includes a method to decrease the toxicity to an antineoplastic agent or increase the therapeutic index of an antineoplastic agent administered for the treatment of a solid growth of abnormally proliferating cells, comprising administering an antioxidant prior to, with, or following the antineoplastic treatment.
Owner:SALUTRIA PHARMACEUTICALS LLC
Thiazole couplet pyrazolone series compound and application of the same as Bcl-2 family protein antagonist
InactiveCN101343268ANovel structureHigh cytotoxic activityOrganic active ingredientsOrganic chemistryThiazoleMda mb 231
The invention discloses a thiazole bipyrazolone compound as well as applications thereof in preparing a small molecular inhibitor of Bcl-2 family proteins and antitumor drugs, the thiazole bipyrazolone compound has the above structural formula, and the thiazole bipyrazolone compound has the activity for inhibiting the combination of Bcl-xL and natural substrate polypeptide (Bid BH3 polypeptide) in the micromole range, and can serve as the small molecular inhibitor of the Bcl-2 family proteins for inhibiting the anti-apoptosis activity thereof; and the compound shows a certain inhibitory activity to human breast cancer MDA-MB-231 cells and MCF-7 cells, and is expected to be developed into the antitumor drugs of targeted Bcl-2 family proteins.
Owner:SHANGHAI INST OF ORGANIC CHEM CHINESE ACAD OF SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com